Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672215 | 1.00 | MMP14 (0.55) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL12134558 | 1.00 | MMP14 (0.55) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL31158287 | 1.00 | MMP14 (0.55) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL31158285 | 1.00 | MMP14 (0.55) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL25717405 | 0.93 | MMP14 (0.46) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL25712980 | 0.91 | MMP14 (0.44) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL25210577 | 0.87 | MMP14 (0.38) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL12133415 | 0.87 | MMP14 (0.38) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL17780682 | 0.85 | MMP14 (0.56) | MMP14KDM4EGAAALDH1A1KMT2A | |
| SCHEMBL2002779 | 0.84 | MMP14 (0.78) | MMP14GAAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960543-B2 | Nucleoside or nucleotide derivative and use thereof | RIKEN (JP) | 2011-06-14 | — | — | US | claimed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | claimed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | claimed |
| US-7960543-B2 | Nucleoside or nucleotide derivative and use thereof | RIKEN (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | DUT, NT5C3B, NT5C | MMP14 4627/4885KDM4E 172/4885GAA 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.